Janux Therapeutics, Inc. (JANX) |
|
12.1 0.5 (4.31%)
|
03-31 16:00 |
|
Open: |
11.65 |
Pre. Close: |
11.6 |
|
High:
|
12.42 |
Low:
|
11.65 |
|
Volume:
|
89,102 |
Market Cap:
|
565(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:19:52 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 17.39 One year: 20.29 |
| Support: |
Support1: 10.86 Support2: 9.04 |
| Resistance: |
Resistance1: 14.89 Resistance2: 17.37 |
| Pivot: |
12.21  |
| Moving Average: |
MA(5): 11.81  MA(20): 12.95
MA(100): 15.66 MA(250): 14.07 |
| MACD: |
MACD(12,26): -1.4 Signal(9): -1.5 |
| Stochastic oscillator: |
%K(14,3): 29 %D(3): 22.2 |
| RSI: |
RSI(14): 39.5 |
| 52-week: |
High: 23.63 Low: 9.39 |
| Average Vol(K): |
3-Month: 124 (K) 10-Days: 115 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JANX ] has closed above bottom band by 47.1%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.19 - 13.26 |
13.26 - 13.31 |
|
Low:
|
11.08 - 11.14 |
11.14 - 11.19 |
|
Close:
|
11.51 - 11.61 |
11.61 - 11.69 |
|
Company Description |
|
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California. |
Headline News |
Wed, 15 Mar 2023
7 Biotech Stocks That Could Be the Next Big Thing - Nasdaq
Wed, 15 Mar 2023
HC Wainwright Comments on Janux Therapeutics, Inc.'s Q1 2023 ... - MarketBeat
Fri, 10 Mar 2023
Janux Therapeutics Q4 EPS Beats Analyst Estimates and Reports ... - Best Stocks
Fri, 10 Mar 2023
Housing, Manufacturing Stats Due Next Week - Baystreet.ca
Fri, 10 Mar 2023
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 ... - Business Wire
Tue, 14 Feb 2023
Janux Therapeutics to Participate in Novel IO Panel Discussion at ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
11 (%) |
|
% Held by Institutions
|
103.5 (%) |
|
Shares Short
|
2,150 (K) |
|
Shares Short P.Month
|
2,390 (K) |
Stock Financials |
|
EPS
|
-1.56 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.05 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-844.1 |
|
Return on Assets (ttm)
|
-10.2 |
|
Return on Equity (ttm)
|
-17.1 |
|
Qtrly Rev. Growth
|
56.4 |
|
Gross Profit (p.s.)
|
-0.55 |
|
Sales Per Share
|
0.17 |
|
EBITDA (p.s.)
|
-1.49 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-41 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
-7.76 |
|
PEG Ratio
|
-1.3 |
|
Price to Book value
|
1.33 |
|
Price to Sales
|
68.3 |
|
Price to Cash Flow
|
-12.15 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
